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A B S T R A C T
Background: We aimed to report, for the ﬁrst time, the results of the Iranian National Population-based Cancer
Registry (INPCR) for the year 2014.
Methods: Total population of Iran in 2014 was 76,639,000. The INPCR covered 30 out of 31 provinces (98% of
total population). It registered only cases diagnosed with malignant new primary tumors. The main sources for
data collection included pathology center, hospitals as well as death registries. Quality assessment and analysis
of data were performed by CanReg-5 software. Age standardized incidence rates (ASR) (per 100,000) were
reported at national and subnational levels.
Results: Overall, 112,131 new cancer cases were registered in INPCR in 2014, of which 60,469 (53.9%) were
male. The diagnosis of cancer was made by microscopic conﬁrmation in 76,568 cases (68.28%). The ASRs of all
cancers were 177.44 and 141.18 in male and female, respectively. Cancers of the stomach (ASR=21.24),
prostate (18.41) and colorectum (16.57) were the most common cancers in men and the top three cancers in
women were malignancies of breast (34.53), colorectum (11.86) and stomach (9.44). The ASR of cervix uteri
cancer in women was 1.78. Our ﬁndings suggested high incidence of cancers of the esophagus, stomach and lung
in North/ North West of Iran.
Conclusion: Our results showed that Iran is a medium-risk area for incidence of cancers. We found diﬀerences in
the most common cancers in Iran comparing to those reported for the World. Our results also suggested geo-
graphical diversities in incidence rates of cancers in diﬀerent subdivisions of Iran.
1. Introduction
Cancer was the second leading cause of death with over 8.7 million
deaths in 2015 [1]. It is predicted that the prevalence of cancers in
developed countries will increase by 45% by the year 2025 [2]. Ac-
cording to the Globocan 2018 estimates, the shares of cancer incidence
and deaths in Asia are 48.4% and 57.3%, respectively [3–5]. Population
aging, population growth and increasing trends in the prevalence of risk
factors of cancer in the developing world (consisting of 82% of the
world population) resulted in increasing incidence and mortality of
cancers among these populations [6].
Iran, as a developing country, has been faced with the above-men-
tioned situations, especially the population aging and increase in cancer
risk factors during the recent decades [7]. After traﬃc accident and
cardiovascular mortality, cancer was suggested as the third leading
cause of death in Iran [7,8]. Regional reports from Iran showed in-
creasing trends in the incidence of diﬀerent cancers, especially breast
and colorectal cancers [9,10]. Therefore, cancer control programs are
among the main agenda for the control of noncommunicable diseases
(NCDs) in Iran [11].
Access to epidemiological data on cancer has a pivotal role in cancer
control planning. This may be suﬃciently achieved by running
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population-based cancer registries. Cancer registry activities were
started in Iran in 1950s [12]. In 1984 a bill mandating the report of all
tissues “diagnosed or suspected as cancer tissue” was passed by the
Iranian Parliament [13]. Accordingly, the Iranian Ministry of Health
and Medical Education (MOHME) started its formal cancer registry
activities in 1986. The plan was to collect data on cancer cases from
pathology centers, called pathology-based cancer registration and re-
sults were published as diﬀerent annual reports [14]. However, the
major limitation of this plan was underestimation of incidence rates
[15], suggesting the need for more reliable cancer data by establishing
population-based cancer registries (PBCR). During early 2000s, the
MOHME started collaborative works with the Digestive Diseases Re-
search Center of Tehran university of Medical Sciences, the Interna-
tional Agency for Research on Cancer (IARC) and local universities to
run regional PBCRs in selected provinces. These collaborations resulted
in establishment of two population-based cancer registries in Ardabil
[16] and Golestan provinces [9,10,17], which were accepted as voting
members of the International Association of Cancer Registries (IACR)
and the data of the Golestan Population-based Cancer registry (GPCR)
were published in the IARC's Cancer Incidence in Five Continents [18].
In the late 2000s, similar regional PBCRs were started in some other
provinces and diﬀerent reports were published [19–21]. These regional
reports were used in international projects including the Globocan
project [6,22,23] to estimates cancer statistics for Iran at national level.
The major limitations of these regional PBCRs included lack of orga-
nizational structures, poor access to ﬁnancial support and possible
discrepancies in operational plans and methods of data collection.
Therefore, in early 2010s, the MOHME planned to establish an in-
tegrated Iranian national population-based cancer registry (INPCR).
The main aims of the INPCR include: to develop comprehensive na-
tional guideline for population-based cancer registries, to support and
supervise establishment and maintenance of regional cancer registries
in provinces, to collect and aggregate regional cancer data to produce
and publish national cancer statistics.
In this paper, for the ﬁrst time, we report the main ﬁndings of
INPCR for the year 2014 which cover 98% of Iran population.
2. Methods
2.1. Population coverage
Population statistics at provincial and national levels for the year
2014 were obtained from the statistics oﬃce of the Deputy of health of
the MOHME. It was a projection from the national census data of the
year 2011 obtained from the statistical center of Iran [24]. Fig. 1 shows
the population pyramid of Iran in 2014. Total population of Iran in
2014 was 76,639,000, including 38,600,000 men and 38,069,000
women.
2.2. Organization of INPCR
Iran consists of 31 provinces and there are 60 medical universities in
these provinces (some provinces consist of 2 or more medical uni-
versities). There are 248 public and 76 private hospitals in Iran. The
number of pathology centers are 255 and 961 in public and private
sectors, respectively. Treatment of cancer patients is not free of charge.
According to the report of the statistical center of Iran, about 97% of
Iranian population are covered by health insurance and almost all
cancer patients refer to public and private hospitals in Iran for diag-
nostic and therapeutic services [25].
To cover all Iranian population, we needed to consider all 60
medical universities as administrative units of the MOHME. Therefore,
the INPCR included a national-level secretariat (the INPCR secretariat)
and 60 university-level secretariats. All of the university-level (re-
gional) cancer registries are now active and collect cancer data from
their population, prospectively. In provinces with only one medical
university, the total population of the province is covered by the uni-
versity cancer registry. Therefore, in these provinces, the university-
level data (representative of total population of the province) were
directly submitted to the INPCR secretariat. But, in provinces with two
or more medical universities, university-level data were merged into
provincial-level data and then the provincial-level data were submitted
to the INPCR secretariat. Finally, the provincial-level data were merged
into the national-level database by the INPCR secretariat.
2.3. Data collection
INPCR started data collection with data of the year 2014. The
process of data collection for the year 2014 was ﬁnished in mid-2016.
To ensure comparability of data, the INPCR developed a national
guideline for PBCRs considering the standard protocols and operational
plans suggested by international references including the IARC and
IACR [26,27]. Then, the INPCR guideline was delivered to medical
universities and all staﬀ of university cancer registries were trained to
follow the guideline and implement PBCRs on the population covered
by their university. Three national level and 5 regional (3 days)
workshops were held during which 150 cancer registry staﬀ from all 60
universities were trained. Based on the guideline, the INPCR registered
Fig. 1. Population of Iran, 2014.
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only cases with new primary tumors with malignant behavior. For tu-
mors of the central nervous system (CNS) and bladder, the INPCR re-
gistered only malignant tumors. In case of metastasis or recurrence,
only initial primary tumors were registered. The multiple primary rule
developed by IARC has been considered to determine occurrence of
multiple primary tumors in a patient [28]. The standard patient regis-
tration form was developed considering mandatory and optional items
for data collection. To ensure collection of accurate data on geo-
graphical distribution of cancers in diﬀerent subdivisions, data on pa-
tients' place of residence was collected as a mandatory item.
The main sources for data collection included pathology reports
form pathology centers, clinical/paraclinical data from hospitals.
Overall, the data were collected from 1540 sources including 324
hospitals and 1216 pathology labs. Mortality data were also collected
from death registry units of the medical universities. Using a linkage
method, the mortality data were matched against cancer incidence data
to identify cases with diagnosis made by death certiﬁcate only (DCO).
The linkage was basically performed using patients' national identiﬁ-
cation number (national ID). But, because of lack national ID in some
patients (about 40% of patients), other demographic information in-
cluding ﬁrst name, last name, father name, age and gender were also
considered for linkage. Based on facilities available in each source, the
secretariat of university cancer registries considered a combination of
diﬀerent methods for data collection including electronic-based or
paper-based methods. In sources with electronic data collection facil-
ities (using online or oﬄine software), the mandatory and optional
items (if applicable) were exported from the source-speciﬁc software
into an excel ﬁle and the staﬀ of university cancer registries collected
the exported data ﬁles. But, in sources without these electronic facil-
ities, the data were collected using paper-based registration forms.
The INPCR also developed a speciﬁc web-based application to fa-
cilitate and secure transmission of data from the university cancer
registry secretariats to the INPCR secretariat, called Sima-ye-Saratan.
Each university cancer registry secretariat could access the university
dashboard using a username and password. Data could be entered into
the Sima-ye-Saratan by data entry form (for individual data) or using
import panel for batch ﬁles.
At the time of data entry, patient's place of residence was coded
using an oﬃcial list of divisions and subdivisions of Iran, obtained from
the Statistical Center of Iran (SCI). The INPCR used the ﬁrst revision of
the 3rd edition of the International Classiﬁcation of Diseases for
Oncology (ICD-O-3) for coding tumor characteristics (i.e. topography,
morphology, behavior and grade) [29]. Deﬁning ICD-O code for tumor
information is routinely performed by university cancer registry se-
cretariat for all records at the time of data entry.
2.4. Data processing and quality control
After data entry, the staﬀ of university cancer registry secretariat
performed data processing and quality control using facilities provided
by the Sima-ye-Saratan including person search, checking for duplicate
records at patient and tumor levels and checking for internal con-
sistency (cross checks between items including sex-tumor site, age-
tumor site, …). The data from already existing cancer registries (e.g.
Golestan Polpulation-based Cancer registry) was also imported in the
Sima-ye-Saratan and was processed similar to other new registries using
the national guideline. At the ﬁrst step, patient's information was en-
tered into Sima-ye-Saratan. Then the registrar checked the dataset for
potential duplicate records. If there was a duplicate record in the da-
taset, patient's information was updated and if there was no duplicate
record in the dataset, the registrar continued to ﬁll in tumor informa-
tion. After entering tumor information and passing the internal con-
sistency check, the record was conﬁrmed as a new cancer case. If a
patient referred to another province for seeking medical services, the
registrar in the host province entered the code of patient's home pro-
vince in the ﬁeld of place of residence. Then the registrar in the patient's
hope province continued processing of patient's records (person search,
…). Therefore, there was no chance for duplicate registration of a pa-
tient when he/she referred to another province. After ﬁnishing the data
processing and quality control by each university cancer registry, the
university or provincial-level data were submitted to the INPCR secre-
tariat, annually. The INPCR secretariat performed additional checks on
quality of data, especially measures of the completeness and accuracy
of data. If needed, the university data were returned to the university
cancer registry secretariat for revisions/corrections or clariﬁcations.
After passing the ﬁnal INPCR quality control, the data were accepted
and used for ﬁnal analysis.
2.5. Statistical analysis
Data were analyzed and reported as numbers, percent, crude in-
cidence rates, age speciﬁc incidence rates and age standardized in-
cidence rates (ASR) at provincial and national levels. The ASRs were
calculated by Canreg-5 software [30] using the world standard popu-
lation in 18 age categories of 5 years each (0–4, 5–9…, 85+). All rates
were expressed per 100,000 population. The Segi-Doll world popula-
tion was used to calculate ASRs [31].
3. Results
The INPCR could collect cancer incidence data for the year 2014
from 30 out of 31 Iranian provinces consisting of 76,639,000 Iranian
population (98% of total population). Only one province (Qom pro-
vince) was excluded from this analysis due to lack of data.
Overall, 112,060 new cancer cases (including skin cancers) were
registered in INPCR in 2014. 60,432 (53.9%) of these cases were male
and 51,628 cases (46.1%) were female. Patients' age was unknown in
71 (0.06%) of registered cases. The median (interquartile range) of
cancer patients' age were 64 (53–75) and 56 (44–68) in male and fe-
male, respectively.
The diagnosis of cancer was made by microscopic conﬁrmation
(pathology or cytology) in 76,568 cases (68.32%). The method of di-
agnosis was DCO in 14,568 cases (13.00%). The remaining 21,001
patients (18.73%) were diagnosed by clinical only or clinical in-
vestigation methods. The primary site of cancer was unknown in 6298
cases (5.62%) including 3415 (5.65%) and 2883 (5.58%) in male and
female, respectively. Patient's age was unknown in 37 (0.06%) men and
34 (0.06%) women. The distribution of diagnosis methods for all sites
as well as for most common cancers in male and female are shown in
Table 1. The distribution of methods of diagnosis by diﬀerent provinces
Table 1
Distribution of diagnosis methods for most common cancers in Iranian National
Population based Cancer registry (INPCR)-2014.
MVa Clinicalb DCOc
Number Percent Number Percent Number Percent
Male Stomach 4575 63.97 1123 15.70 1454 20.33
Prostate 4199 70.57 895 15.04 856 14.39
Colorectal 2711 71.45 610 16.08 473 12.47
Bladder 4058 84.93 530 11.09 190 3.98
Lung 1954 46.26 982 23.25 1288 30.49
All sites 40730 67.40 11179 18.50 8523 14.10
Female Breast 10498 80.00 2002 15.26 623 4.75
Colorectal 2156 73.53 419 14.29 357 12.18
Stomach 1911 57.06 544 16.24 894 26.69
Thyroid 2610 89.60 266 9.13 37 1.27
Leukemia 377 48.27 311 39.82 93 11.92
All sites 35785 69.31 9818 19.02 6025 11.67
a Microscopic veriﬁcation (including pathology and cytology).
b Clinical only or clinical investigations.
c Death certiﬁcate only.
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have been presented in supplementary Table 1.
The crude rate and ASR of all cancers (including skin cancers) in
total Iranian population were 146.22 and 158.41 per 100,000, respec-
tively. The ASRs of all cancers were 177.44 and 141.18 per 100,000 in
male and female, respectively. The ASRs of all cancers, excluding non-
melanoma skin cancer were 157.04 and 129.52 per 100,000 in male
and female, respectively.
Cancers of the stomach (ASR=21.24), prostate (18.41), colorectal
(16.57), bladder (14.30) and lung (12.7) were the most common can-
cers in men and the top ﬁve cancers in women were malignancies of
breast (34.53), colorectal (11.86), stomach (9.44), thyroid (6.98) and
leukemia (5.4). Table 2 shows the number, percent, crude rate and ASR
of 10 most common cancers in male and female in Iran. Number of
cases, percent, age speciﬁc rates, crude rates and age standardized in-
cidence rates (ASR) (per 100,000) of all cancer sites for male and fe-
male have been shown in supplementary tables 2 and 3, respectively.
Our results suggested very low incidence rate for cervix uteri cancer
in Iran. The crude rate and the ASR of cervix uteri cancer were 1.76 and
1.78 per 100,000, respectively.
Figs. 2 and 3 show age speciﬁc incidence rates of 5 most common
cancers in Iran in 2014 for male and female, respectively. The highest
age speciﬁc rates were seen in the age group 75–85 years in almost all
cancers. The age speciﬁc rate of breast cancer showed an early peak in
the age group 40–50 years.
Our ﬁndings suggested high incidence of cancers of the esophagus,
stomach and lung in provinces located in North/ North West of Iran.
Our results also showed higher incidence rates for malignancies of the
breast, colorectal, skin, thyroid, bladder, prostate and ovary in central
parts of Iran. Figs. 4 and 5 show the distribution of 10 most common
cancers in diﬀerent regions and provinces of Iran in 2014 for male and
female, respectively.
4. Discussion
Population-based cancer registries play a crucial role in cancer
control planning. This very important data is not available in many low
and middle-income countries where the cancer burden is increasing. We
have established the national population-based cancer registry in Iran
and provide the ﬁrst report of cancer incidence for year 2014.
Regarding the quality evaluation of data, our ﬁndings suggested
relatively low MV (68.28%) and high proportions for DCO (12.99%)
and unknown primary site (5.62%). But, Comparing the INPCR data
quality indicators with those from other high-quality cancer registries
in the region [32,33], our quality indices are within acceptable ranges.
For example, according to the reports of the volume XI of the cancer
incidence in ﬁve continents, there were lower proportions of MV and
higher proportions of DCO in caner registries from South America,
Africa and parts of Asia [33]. In addition, it should be mentioned that
INPCR started data collection at national level with the new population-
based plan in 2014 and the resulted quality indicators are encouraging
for the beginning year of a national level population-based cancer
registry in a large country like Iran.
The incidence rates of all cancers, excluding non-melanoma skin
cancer were 157.04 and 129.52 per 100,000 in Iranian male and fe-
male, respectively. These rates were considerably low when compared
with those reported globally for men (204.9) and women (165.2) [3]. In
addition, the rates were much lower comparing to incidence rates re-
ported from developed countries and even some neighboring popula-
tions (Turkey) [6]. According to the volume XI of the cancer incidence
in ﬁve continents, higher rates of cancers were reported from diﬀerent
cancer registries from developed countries (e.g. USA, male= 338.4,
female= 282.1; Australia, male= 388.2, female= 284.5) and also
some cancer registries from Turkey (e.g. Izmir, male= 318.5, fe-
male= 204.6) [33]. According to the Globocan [3,6] as well as other
local reports [34], Iran is a medium-risk area for incidence of cancers.
Therefore, reports suggesting Iran as a high-risk area for cancers or
local claim of cancer tsunami in Iranian population are not true.
Stomach cancer was the most common malignancy in Iranian male
population. The Globocan 2018 project suggested lung cancer as the
most common cancer in the World's male population. Stomach cancer
was reported as the fourth cancer in male for the World population [3].
The high incidence rate of stomach cancer in Iran may be due to a high
prevalence of Helicobacter pylori infection as well as several local spe-
ciﬁc risk factors including higher salt intake, dietary habits and opium
consumption [35–40]. Further studies are warranted to clarify risk
factors and consequently design appropriate programs for prevention of
gastric cancer in Iran.
As reported for other populations, breast cancer was the most
common cancer in Iranian female population. We also found an early-
peaking age speciﬁc rates of breast cancer in young age women (Fig. 3).
Diﬀerent reports suggested increasing trend in the incidence of breast
cancer in total as well as in young age women, especially in the de-
veloping world [41,42]. There was no screening program for breast
cancer at national and regional levels in Iran. Therefore, the increasing
trend may be due to increase in the prevalence of previously known risk
factors (e.g. reproductive factors, obesity, dietary habits) [41,43–45].
But these known risk factors may only explain a portion of the high
incidence of this cancer in high-risk population. In other words, there
may be unknown risk factors for high rates of breast cancer in diﬀerent
population [41]. Therefore, it is recommended to consider compre-
hensive population-based studies to identify most important known as
well as unknown risk factors of breast cancer in Iranian female popu-
lation, especially in the young women. This will help policy makers to
develop targeted risk reduction interventions and will consequently
help designing and implementation of more eﬀective breast cancer
controlling program among Iranian population.
The ASR of cervix uteri cancer in Iran was 1.78 per 100,000. The
rates of cervical cancer in Iran was considerably low comparing to the
global rates reported by the Globocan project (13.1 per 100,000) [3].
Previous reports from Iran also suggested low incidence rates for this
cancer in Iranian population [7]. Speciﬁc religious beliefs and rules in
Iran may be considered as the main indicator for low rates of this cancer
in our population. In the other hand, these religious beliefs may act as a
barrier to seeking medical care and this in turn may result in under-
estimation of incidence cervix uteri cancer. Further studies are
Table 2
The number, percent, crude rate and age standardized incidence rates (ASR)
(per 100,000) of 10 most common cancers in male and female in Iran (2014).
Number Percent Crude rate ASR
Male Stomach 7150 11.83 18.52 21.24
Prostate 5949 9.84 15.41 18.41
Colorectal 5644 9.34 14.62 16.57
Bladder 4776 7.90 12.37 14.30
Lung 4222 6.99 10.94 12.70
Leukaemia 2888 4.78 7.48 8.32
Brain, nervous system 2412 3.99 6.25 6.66
Esophagus 2178 3.60 5.64 6.47
Non-Hodgkin lymphoma 1929 3.19 5.00 5.32
Larynx 1418 2.35 3.67 4.32
All sites 60432 100 156.56 177.44
All site, but C44 53662 – 139.02 157.04
Female Breast 13120 25.41 34.49 34.53
Colorectal 4217 8.17 11.09 11.86
Stomach 3348 6.48 8.80 9.44
Thyroid 2912 5.64 7.66 6.98
Leukaemia 1891 3.66 4.97 5.40
Lung 1844 3.57 4.85 5.21
Brain, nervous system 1810 3.51 4.76 4.88
Esophagus 1776 3.44 4.67 5.13
Ovary 1657 3.21 4.36 4.52
Uterus 1304 2.53 3.43 3.67
All sites 51628 100 135.72 141.18
All site, but C44 47574 – 125.07 129.52
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warranted to clarify the point in Iranian population.
Our results suggested geographical variations among diﬀerent sub-
divisions (provinces) of Iran. We found higher rates of cancers of the
esophagus, stomach and lung in provinces located in North/ North West
of Iran. Similar trends were previously reported for Northern parts of
Iran and its neighboring countries in West of Asia [46,47]. This may be
due to higher prevalence of risk factors including smoking in these
regions [48]. Diﬀerences in life style and behavioral factors related to
geographical latitude and altitude may also partly explained higher
incidence of these malignancies in North/ North West of Iran. One
possible explanation is related to cold weather and consequently higher
usage of biomass as the primary fuel for cooking and heating in poorly
ventilated houses in the northern areas. This may in turn result in
producing considerable amounts of polycyclic aromatic hydrocarbons
(PAH)-a known risk factor for upper GI and lung cancers [49,50].
Further regional, national and even international studies are needed to
determine speciﬁc risk factors for high rates of upper gastrointestinal
and lung cancers in these high-risk areas.
We also found higher incidence rates for malignancies of the breast
and colorectal cancers in central parts of Iran. Central parts of consist of
very big cities with higher rates of urbanization and consequently
higher prevalence of risk factors related to westernized life style (e.g.
obesity, un-healthy diet, low physical activity). Reports from a national
wide study on risk factors for non-communicable diseases also sug-
gested higher prevalence of these risk factors in these areas [51]. As
reported, these are known risk factors for diﬀerent types of cancers
including breast and colorectal cancers further epidemiological studies
may elucidate the role of known risk factors and investigate possible
unknown risk factors in these high-risk areas [41,45].
Our results showed relatively high incidence of CNS and bladder
cancers in Iran. There are no evidence available regarding the etiologies
of high rates of these cancer in Iran, although some risk factors were
proposed for bladder cancer including infectious disease (schistoso-
miasis and human papillomavirus) and smoking [52]. Further studies
are need to clarify the reasons for high rates of these cancers in Iran.
The most important limitation of this study was relatively low
quality of data, although the indices of data quality were almost ac-
ceptable according to similar data reported in international project
including cancer incidence if ﬁve continents. Anyway, the author are
aware regarding the necessity of improving the quality of INPCR data
and diﬀerent procedures have been considered and the will hopefully
result in improvement in the data quality in next years.
In conclusion, our ﬁndings suggested that comparing the incidence
of rates of cancers in Iran with the average rates reported for the World,
Iran is a medium-risk area for incidence of cancer. Cancers of the sto-
mach and breast were the most common cancers in Iranian male and
female, respectively. Our results also suggested geographical dis-
crepancies in incidence rates of cancers in diﬀerent subdivisions of Iran.
Cancers of the stomach, esophagus and lung were more common in
North and North whiles higher rates of cancers of the breast and col-
orectal were found in central parts of Iran. INPCR data may be helpful
to inform local and national planners of the most common cancers at
Fig. 2. Age speciﬁc incidence rates (per 100,000) of most common cancers in Iran, 2014 (Male).
Fig. 3. Age speciﬁc incidence rates (per 100,000) of most common cancers in Iran, 2014 (Female).
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Fig. 4. Population number, total cases and age standardized incidence rates (per 100,000) of 10 most common cancers and all cancers in diﬀerent regions and
provinces of Iran, 2014 (Male). *C44= non-melanoma skin cancer. (The red and green colors indicate the highest and the lowest incidence rates, respectively). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Population number, total cases and age standardized incidence rates (per 100,000) of 10 most common cancers and all cancers in diﬀerent regions and
provinces of Iran, 2014 (Female). *C44= non-melanoma skin cancer. (The red and green colors indicate the highest and the lowest incidence rates, respectively).
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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regional and national levels and may help them to design and imple-
ment targeted eﬀective controlling programs for these cancers.
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